Non-invasive Strategies for Chronic Manipulation of DREADD-controlled Neuronal Activity
August 25th, 2019
13.5K views
Here we describe two non-invasive methods to chronically control neuronal activity using chemogenetics in mice. Eye-drops were used to deliver clozapine-N-oxide (CNO) daily. We also describe two methods for prolonged administration of CNO in drinking water. These strategies for chronic neuronal control require minimal intervention reducing animals’ stress.
Overview
This study presents two non-invasive methods for chronic control of neuronal activity using chemogenetics in mice. It focuses on less invasive delivery techniques for clozapine-N-oxide (CNO), utilizing eye drops and drinking water to minimize animal stress while allowing for sustained neuronal activation.
Key Study Components
Area of Science
- Neuroscience
- Chemogenetics
- Animal Behavior
Background
- Remote control of neuronal activity is crucial for various experimental paradigms.
- DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) are commonly used for this purpose.
- Traditional methods can involve significant stress and intervention for the animals, which this study aims to address.
Purpose of Study
- To provide alternatives for chronic CNO administration in mice.
- To minimize stress in animals during neuronal activation protocols.
- To validate the effectiveness of the new delivery methods.
Methods Used
- The study uses a mouse model for chemogenetic manipulation.
- Delivery of CNO was done either via repetitively applying eye drops or administering it through drinking water.
- Protocols were developed for both approaches, including acclimatization phases for animals.
- Detailed surgical and administration procedures were described to ensure repeatability.
Main Results
- Repetitive CNO delivery through eye drops significantly induced cFos expression in infected neurons.
- The effectiveness of CNO persisted during repetitive exposures.
- Daily water consumption was not adversely affected by the CNO addition, indicating a successful method of administration without negative impacts on hydration.
Conclusions
- This study demonstrates effective, non-invasive methods for chronic neuronal control, facilitating cleaner experimental design.
- These protocols can be adapted to various experimental settings with minimal animal stress.
- Insights gained can enhance understanding of neuronal mechanisms and their control.
Frequently Asked Questions
What are the main advantages of the new CNO delivery methods?
The new methods are non-invasive and minimize animal stress. They also enable chronic control of neuronal activity over extended periods.
How is the CNO administered via eye drops?
CNO is delivered as a stable droplet close to the cornea without touching the eye, ensuring accurate dosage while minimizing stress.
What is the significance of the study's findings?
The findings validate that chronic neuronal activation can be achieved with minimal intervention, allowing for studies that require sustained neuronal control.
Can these protocols be adapted for various experimental designs?
Yes, the protocols can be tailored to accommodate different DREADD variants and experimental setups, enhancing their versatility.
What types of data are obtained from these methods?
The methods yield data related to neuronal activity, including molecular readouts such as cFos expression in response to CNO delivery.
What key considerations must be taken when implementing these methods?
Researchers should acclimate animals properly to handling and ensure accurate dosing of CNO based on body weight to optimize results.
Executive Industry Relevance
Non-invasive chronic modulation of neuronal activity addresses a key bottleneck in preclinical neuroscience by reducing animal stress and enabling longitudinal studies. This supports target validation and mechanistic de-risking in CNS drug discovery by providing reliable, scalable chemogenetic control. The approach enhances predictive confidence in behavioral and pharmacological assays relevant to neuropsychiatric indications.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through sustained neuronal activation or inhibition.
- Operational Value: Reduces variability from acute stress responses, improving data consistency across cohorts.
- Predictive Value: Supports target confidence by linking chronic pathway modulation to phenotypic readouts like cFos induction.
Screening & Assay Development
- Scientific Value: Provides a standardized platform for evaluating compound effects on chronically modulated neural circuits.
- Operational Value: Eye-drop and drinking water delivery methods are low-cost, scalable, and compatible with high-throughput handling.
- Assay Readiness: Enables reproducible, quantitative neuronal activation readouts without surgical re-intervention.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant modeling by maintaining target engagement over extended periods.
- Operational Value: Minimizes confounding variables from surgical delivery systems, improving cross-study comparability.
- Predictive Confidence: Facilitates risk-adjusted advancement decisions by demonstrating sustained DREADD-mediated effects.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead optimization, enabling chronic mechanistic probing prior to phenotypic screening.
- Discovery Biology: Supports hypothesis testing and pathway clarification via long-term neuronal modulation.
- Screening: Delivers assay-ready systems with consistent, quantifiable outputs for compound evaluation.
- Analytics: Generates measurable endpoints like cFos expression to compare activation states across conditions.
- Translational Research: Connects target modulation to behavioral outcomes through chronic, minimally invasive control.
- Enterprise Reuse: Establishes a reusable chemogenetic platform adaptable across DREADD variants, brain regions, and species.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target-mechanism relationships through sustained pathway modulation.
- Operational Value: Standardizes CNO delivery across labs, reducing technical variability and training burden.
- Strategic Value: Improves go/no-go decision quality by reducing false negatives from stress-induced artifacts.
- Portfolio Impact: Enables risk-aware prioritization of CNS targets with validated chronic modulation capacity.
Implementation Considerations
- Requires expertise in stereotaxic surgery, viral vector handling, and chemogenetic controls.
- Depends on access to micropipettes, stereotaxic frames, and fluorescence imaging systems for validation.
- Necessitates standardized animal acclimation protocols to handling and delivery routines.
- Must account for species-specific differences in metabolism and blood-brain barrier penetration of CNO.
- Limited by the need for dose optimization to avoid off-target effects, particularly at high concentrations.
Biopharma FAQs
Why does chronic CNO delivery matter for target validation?
Chronic delivery enables sustained target engagement, which is essential for evaluating long-term therapeutic effects and mechanistic durability in target validation studies.
How does isolating the independent variable (CNO dose) support discovery pipeline decisions?
By controlling CNO concentration via drinking water or eye drops, researchers can isolate its effect on neuronal activity, enabling clear dose-response relationships for target de-risking.
What quantitative dependent variable measurements enable target assessment?
cFos expression serves as a quantitative proxy for neuronal activation, allowing objective comparison of DREADD-mediated effects across treatment conditions.
Why do replication requirements matter for cross-functional collaboration?
Reproducible CNO delivery across cohorts ensures consistent target modulation, which is critical for aligning discovery, preclinical, and translational teams on target validity.
What statistical analysis capabilities are required before implementing these methods?
Baseline comparison and dose-response analysis are needed to distinguish specific DREADD effects from non-specific activation, ensuring reliable interpretation of neuronal activity data.
Chapters in this video
0:04
Title
0:53
Hippocampal Adeno-associated Virus Injection
2:10
Repetitive Clozapine-N-Oxide (CNO) Delivery
3:20
Chronic CNO Treatment
4:07
Restricted CNO Treatment
5:01
Data Analysis
6:15
Results: Representative Effects of Repetitive and Chronic CNO Delivery
7:40
Conclusion
